Figure 5From: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]Creatinine and alkaline phosphatase up to 36 months since trial entry (adjusted for baseline differences between groups). (a) Total creatinine (μmol/l); and (b) total alkaline phosphatase (u/l).Back to article page